Laddar populära aktier...
Copenhagen, Denmark, 21 November 2024 - Today is the first day for the exercise of Curasight A/S’ ("Curasight" or "the Company" - TICKER: CU...
Business Highlights during and after the third quarter of 2024 · Curasight designates brain cancer as initial indication for uTREAT · C...
Copenhagen, Denmark, 20 November 2024 - Curasight A/S ("Curasight" or "the Company" - TICKER: CURAS) hereby announces that the exercise pric...
Brain cancer will be the first indication for Curasight’s uTREAT therapy.
Curasight väljer aggressiv hjärncancer som den första indikationen för uTREAT-behandlingen och planerar att genomföra en kort studie under n...
Copenhagen, Denmark, 14 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasil...
· New patent application related to uTREAT will extend patent protection until 2043 · Application adds several new alpha- and beta-emit...
Den sjunde upplagan av BioStock Life Science Summit går av stapeln 20-21 november, i Lund.
The seventh edition of the BioStock Life Science Summit will take place in Lund on November 20-21.
· Brain cancer (high-grade glioma (HGG)) selected as first indication for uTREAT[®] · Addresses a clear unmet medical need · Clinical...
Curasight has published the full data from an investigator-initiated phase II trial evaluating its uTRACE imaging technology in brain cancer...
Curasight har publicerat fullständiga data från en prövarinitierad fas II-studie som utvärderar uTRACE hos hjärncancerpatienter i tidskrifte...
Copenhagen, Denmark, 8 November 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasiln...
· Curasight’s radiopharmaceutical approach leverages the uPAR theranostic platform with the aim of providing improved diagnosis (uTRACE) ...
Radiofarmakasektorn är på stark frammarsch. En uppsjö av investeringar, förvärv och partnerskap gör området till ett av de hetaste inom onko...
The radiopharmaceutical sector is gaining considerable momentum as companies increasingly recognize its potential to offer highly targeted c...
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRA...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW Z...
In late June, Curasight announced a capital raise package of up to DKK 120 million to finance the ongoing development of its theranostic pla...
I slutet av juni tillkännagav Curasight ett kapitalanskaffningspaket på upp till 120 miljoner DKK för att finansiera den pågående utveckling...
Having secured financing for the ongoing clinical development of uTRACE, Curasight can now enter the next level in developing the therapeuti...
Efter att ha säkrat finansiering för den pågående kliniska utvecklingen av uTRACE kan Curasight nu ta nästa steg i utvecklingen av den terap...
Business Highlights during the second quarter 2024 · Strengthened financial base with funding of DKK 27.
Copenhagen, Denmark, 30 July 2024 - Curasight A / S ("Curasight" or the “Company"- TICKER: CURAS) announces today that it has re-issued a to...
Copenhagen, Denmark, 2 July 2024 – today Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) held an Extraordinary General Meeting ...
Copenhagen, Denmark, 01 July 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) today announces that the directed issues de...
Curasight has enrolled the first patient in its phase II trial with uTRACE in prostate cancer, activating a second USD 500,000 payment from ...
Curasight har rekryterat den första patienten i sin fas II-studie med uTRACE i prostatacancer, vilket aktiverar en andra betalning på 500 00...
Copenhagen, Denmark, 22 June 2024 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilniko...
The Board of Directors is pleased to invite shareholders of Curasight A/S (“Curasight” or the “Company”) to an Extraordinary General Meeting...
· Recruitment of first patient triggers second milestone payment of USD 500.
Partnerskapet med Curium inom prostatacancer fortskrider och Curasight siktar på att accelerera utvecklingen av den terapeutiska plattformen...
The partnership with Curium for diagnosis in prostate cancer is advancing and Curasight aims to accelerate the development of the therapeuti...
Business Highlights during the first quarter 2024 · Announcing the achievement of the first milestone under the agreement with Curium Inc...
Partnerskapsavtalet med Curium förra året är Curasights viktigaste milstolpe hittills.
The partnership deal closed with Curium last year marks the most important milestone for Curasight to date.
· Dosing of first patient expected 2Q 2024 · CTA approval marks progress in development of uTRACE[®] in prostate cancer under the colla...
Copenhagen, April 12, 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) announces that the chairperson of the Board of Di...
Copenhagen, Denmark, 21 March 2024 – today Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) held its Annual General Meeting at t...
I mitten av februari tillkännagav Curasight en företrädesemission om 51,2 miljoner DKK för att påskynda den kliniska utvecklingen av uTREAT ...
In mid February, Curasight announced a DKK 51.2 million rights issue to accelerate clinical development of uTREAT and uTRACE.
Copenhagen, Denmark, 11 March 2024 – Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) announces today it will not proceed with t...
The Board of Directors is pleased to invite shareholders to the Annual General Meeting of Curasight A/S (“Curasight” or the “Company” – TICK...
Copenhagen, Denmark, 23 February 2024 - Today is the first day of the subscription period in Curasight A/S’s ("Curasight" or the “Company" –...
Copenhagen, Denmark, 22 February 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) has prepared and published an informati...
Copenhagen, Denmark, 22 February 2024 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Annual Report for ...
Business Highlights during the fourth quarter 2023 · Encouraging preclinical data using uTREAT in non-small cell lung cancer · Announci...
Last year, a lot of focus for Curasight revolved around prostate cancer and the licensing deal with Curium.
Curasights 2023 kretsade kring prostatacancer och licensavtalet med Curium.
Copenhagen, Denmark, 13 February 2024 - Curasight A/S ("Curasight" or the “Company" – TICKER: CURAS) has today resolved on a new issue of sh...
· Coming Phase I/IIa basket trial planned to include five select cancer indications · Study will apply Curasight’s uPAR theranostic pla...
Prostatacancersamarbetet med Curium är det hittills viktigaste steget som det radiofarmaceutiska bioteknikbolaget Curasight tagit.
The prostate cancer partnership with Curium marks the most pivotal moment for the radiopharmaceutical focused biotech company Curasight to d...
· USD 500.000 payment is the first milestone under the global license and collaboration agreement for the development and commercializati...
Following the Curium deal this spring, Curasight has now submitted a clinical trial application and selected a CRO to carry out a phase II t...
Efter Curium-affären i våras har Curasight nu lämnat in en klinisk prövningsansökan och valt en CRO för att genomföra en fas II-studie med u...
· Company on track to dose first patient in 2Q 2024 · CTA marks progress in development of uTRACE[®] in prostate cancer under the colla...
· Phase 2 study is part of the collaboration between Curasight and Curium announced earlier this year · Appointment of clinical CRO mar...
Looking back at the third quarter, it’s clear that Curasight is keeping the momentum in the development.
När vi ser tillbaka på det tredje kvartalet är det tydligt att Curasight håller tempot uppe i utvecklingen.
Copenhagen, Denmark, 24 November 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasil...
Business Highlights during the third quarter 2023 · Encouraging preclinical data using uTREAT[®] in non-small cell lung cancer · Positi...
Bioteknikbolaget Curasight meddelade nyligen positiva prekliniska resultat för uTREAT vid behandling av icke-småcellig lungcancer.
Biotech company Curasight recently announced positive preclinical results for uTREAT in the treatment of non-small cell lung cancer, showing...
· Preclinical studies show uTREAT[®] effective in treating non-small cell lung cancer (NSCLC) · Data follows recent announcement of po...
Curasight presenterade resultat från fas II-studien med uTRACE vid World Molecular Imaging Congress 2023 i Prag.
Curasight resently presented results from the phase II study with uTRACE in brain cancer at the 2023 World Molecular Imaging Congress held i...
Oral presentation gives more details from the Phase II data where topline results were released on June 29, 2023.
Det andra kvartalet 2023 var på många sätt avgörande för danska Curasight.
In many ways, the second quarter was pivotal for the Danish biotech company Curasight.
Copenhagen, Denmark, 25 August 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilni...
Copenhagen, Denmark, 24 August 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report for t...
Curasights nyligen annonserade prekliniska resultat visade uTREATs potential att hämma glioblastomtillväxt.
Curasight’s recently announced preclinical results showed uTREAT’s potential in inhibiting glioblastoma growth.
· uPAR-PET with [68]Ga-NOTA-AE105 (now known as uTRACE[®]) was highly prognostic both regarding progression-free survival and overall sur...
Biotech company Curasight recently revealed preclinical data demonstrating the effectiveness of uTREAT in treating glioblastoma.
Bioteknikbolaget Curasight tillkännagav nyligen prekliniska data som pekar på att uTREAT har effekt vid behandling av glioblastom.
· Preclinical studies show uTREAT[®] efffective in treating aggressive brain cancer · Data supports strategy to move uTREAT[®] into cli...
Copenhagen, Denmark, 26 May 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasilnikof...
Det Köpenhamnsbaserade bioteknikbolaget Curasight släppte nyligen sin rapport för det första kvartalet 2023, som präglades av ett betydande ...
Copenhagen-based biotechnology company Curasight recently released its Q1 2023 report, unveiling a significant stride in its continued journ...
Copenhagen, Denmark, 25 May 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the interim report Q1 2023.
Back in 2021 Curasight presented promising phase II results from an investigator initiated phase II study with uTRACE in prostate cancer.
2021 presenterade Curasight lovande fas II-resultat från en prövarinitierad fas II-studie med uTRACE i prostatacancer.
Köpenhamnsbaserade Curasight har arbetat hårt för att få till ett partneravtal för uTRACE.
Copenhagen-based Curasight has worked tirelessly to secure a partnership deal for uTRACE.
· Curasight to develop its proprietary uTRACE[®] PET imaging technology to obtain regulatory approval in EU and USA, with Curium responsi...
Copenhagen, Denmark, 15 March 2023 – Notice is hereby given of the annual general meeting of Curasight A/S ("Curasight" or the "Company" – T...
When reporting 2022, the Danish cancer company Curasight describes the year as eventful.
När 2022 rapporteras beskriver det danska cancerbolaget Curasight året som händelserikt.
Copenhagen, Denmark, 23 February 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Annual Report for ...
Copenhagen, Denmark, 23 February 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) hereby publishes the Year-end report Oc...
Copenhagen, Denmark, 22 February 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasil...
Copenhagen, Denmark, 16 January 2023 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby announces that CEO Ulrich Krasiln...
När vd Ulrich Krasilnikoff ser tillbaka på tiden sedan Curasight börsintroducerades för två år sedan, så träder bilden av en mycket händelse...
Looking back at the time since Curasight first IPO’ed two years ago, CEO Ulrich Krasilnikoff sees a period where a lot has happened.
